<DOC>
	<DOCNO>NCT00933517</DOCNO>
	<brief_summary>The purpose study assess pathological response rate operable breast cancer patient treat neoadjuvant combination : `` FEC-Taxotere/Vectibix '' .</brief_summary>
	<brief_title>Assessment Efficacy Neoadjuvant Combination : `` Chemotherapy-Targeted Therapy '' Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Age ³ 18 . Performance status £ 2 ( accord WHO criterion ) . Patient histologically confirm , nonmetastatic breast cancer , clinical tumour diameter ³ 2 cm HR negative Her2 negative . Clinical stage II IIIa . Patients previously treat surgery , radiotherapy , hormone therapy chemotherapy.· Haematology : Neutrophil count ≥1.5x109/Lo Platelet count ≥100x109/Lo Leucocyte count &gt; 3,000/mmo Hb &gt; 9g/dl· Hepatic Function : Total bilirubin ≤ 1.5 time upper normal limit ( UNL ) ASAT ≤ 2.5xUNL absence liver metastasis , ≤5xUNL presence liver metastases ALAT ≤ 2.5xUNL absence liver metastasis , ≤5xUNL presence liver metastases Alkaline phosphatase ≤ 2.5 time upper normal limit ( UNL ) · Renal Function· Creatinine clearance ≥50 mL/min serum creatinine ≤1.5xUNL· Metabolic Function Magnesium ≥ low limit normal . Calcium ≥ low limit normal . Patient progressive heart disease , anthracyclines contraindicate ( normal FEV ) . Patient sign consent form participation inclusion trial . Member Social Security scheme ( beneficiary scheme ) accord provision law 9 August 2004 . Male patient . Her2 positive patient Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment . Any form breast cancer describe inclusion criterion , particularly inflammatory and/or overlook form ( T4b T4d ) . Nonmeasurable tumour . Patients already undergone surgery disease primary axillary dissection . Patient already treat new breast cancer . Patient ward . Patient history second cancer , exception situ cervical cancer basocellular skin cancer regard cure . Patient another disease deem incompatible patient include protocol . Heart kidney failure , medullary , respiratory liver failure . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) £ 1 year enrollment/randomization History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan Significant neurological psychiatric abnormality . Symptomatic progressive disorder central nervous system ( CNS ) metastasis initial checkup . Peripheral neuropathy &gt; grade 2 ( NCICTCAE criterion , Version 3.0 ) . History allergy polysorbate 80 . Concomitant treatment trial drug , participation another clinical trial within &lt; 30 day previous chemotherapy . Patient fix address next 6 month live distance treatment centre difficult check progress . Prior antiEGFr antibody therapy ( e.g . : cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( e.g . : erlotinib ) . Known previous ongoing abuse narcotic drug , medication alcohol . Any investigational agent within 30 day initiation study treatment . Must major surgical procedure within 28 day initiation treatment . Subject unwilling unable comply study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>breast cancer , neoadjuvant therapy , chemotherapy , target therapy</keyword>
</DOC>